


Product Name : Etavopivat
Cat. No. : PC-72959
CAS No. : 2245053-57-8
Molecular Formula : C₂₂H₂₃N₃O₆S
Molecular Weight : 457.501
Target : Other Targets
Solubility : 10 mM in DMSO



Biological Activity

Etavopivat (FT-4202) is a novel oral activator of **PKR** that decreases 2,3-DPG levels and hence would increase the HbS O₂ affinity to reduce sickling.

FT-4202 increases the hemoglobin S O₂ affinity to reduce sickling and improve RBC membrane deformability.

Etavopivat (FT-4202) increased Hb-oxygen affinity and reduced sickling under deoxygenation in ex vivo RBCs from donors with sickle cell disease (SCD).

Oral administration of FT-4202 increases Hb and improves RBC parameters in BERK mice.

Etavopivat is currently being evaluated in clinical trials for the treatment sickle cell disease (SCD).

References

Shrestha A, et al. *Blood Adv.* 2021 May 11;5(9):2385-2390.

Forsyth S, et al. *Clin Pharmacol Drug Dev.* 2022 Jan 12.

Schroeder P, et al. *J Pharmacol Exp Ther.* 2022 Mar;380(3):210-219.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com